Warning (2): mssql_query() [function.mssql-query]: Some character(s) could not be converted into client's character set. Unconverted bytes were changed to question marks ('?') (severity 4) [CORE/cake/libs/model/datasources/dbo/dbo_mssql.php, line 181]
$sql = "SELECT TOP 90 [Brokerpress].[comment] AS [Brokerpress__0], CAST(Brokerpress.date AS datetime) AS [date] FROM [brokerpress] AS [Brokerpress] WHERE [Brokerpress].[epic] = 'APH' ORDER BY [Brokerpress].[date] DESC"
mssql_query - [internal], line ?? DboMssql::_execute() - CORE/cake/libs/model/datasources/dbo/dbo_mssql.php, line 181 DboSource::execute() - CORE/cake/libs/model/datasources/dbo_source.php, line 190 DboSource::fetchAll() - CORE/cake/libs/model/datasources/dbo_source.php, line 338 DboSource::read() - CORE/cake/libs/model/datasources/dbo_source.php, line 655 DboMssql::read() - CORE/cake/libs/model/datasources/dbo/dbo_mssql.php, line 643 Model::find() - CORE/cake/libs/model/model.php, line 2031 Controller::paginate() - CORE/cake/libs/controller/controller.php, line 1095 AppController::paginate() - APP/app_controller.php, line 272 AppController::fetch() - APP/app_controller.php, line 320 RssController::all_news() - APP/plugins/profiles/controllers/rss_controller.php, line 128 Object::dispatchMethod() - CORE/cake/libs/object.php, line 116 Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 227 Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194 [main] - APP/webroot/index.php, line 91
Warning (2): Cannot modify header information - headers already sent by (output started at /home/paiuk/public_html/cake/basics.php:111) [APP/views/layouts/rss.ctp, line 2]
$___viewFn = "/home/paiuk/public_html/app/views/layouts/rss.ctp"
$___dataForView = array(
"facebookSession" => 0,
"searchHeader_limit" => null,
"company" => array(
"Company" => array()
),
"brokerpresses" => array(
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array()
),
"items" => array(
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array()
),
"title_for_layout" => "Rss",
"content_for_layout" => "<channel>
<title>Proactiveinvestors United Kingdom Alliance Pharma</title>
<link>http://www.proactiveinvestors.co.uk</link>
<description>Proactiveinvestors United Kingdom Alliance Pharma RSS feed
</description>
<language>en</language>
<pubDate>Wed, 16 May 2012 18:08:07 +0100</pubDate>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<generator>Genera CMS</generator>
<managingEditor>action@proactiveinvestors.com (Proactiveinvestors)</managingEditor>
<webMaster>action@proactiveinvestors.com (Proactiveinvestors)</webMaster>
<atom:link href="http://www.proactiveinvestors.co.uk/LON:APH/Alliance-Pharma/all_news" rel="self" type="application/rss+xml" />
<item>
<title><![CDATA[RNS press release - Notification of Major Interest in Shares ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 14 May 2012 11:09:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notice of AGM ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 10 Apr 2012 12:02:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</guid>
</item>
<item>
<title><![CDATA[Media files - Alliance Pharma CEO looks forward to continued good growth prospects ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</link>
<description><![CDATA[John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.]]></description>
<pubDate>Fri, 30 Mar 2012 13:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Annual Report and Accounts ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 27 Mar 2012 09:00:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Underlying growth of business remains strong ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</link>
<description><![CDATA[<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ]]></description>
<pubDate>Thu, 22 Mar 2012 08:24:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 22 Mar 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</link>
<description><![CDATA[]]></description>
<pubDate>Wed, 21 Mar 2012 13:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 08 Mar 2012 16:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notification of Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 02 Feb 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma remains a ‘buy’ at Investec Securities ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</link>
<description><![CDATA[<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ]]></description>
<pubDate>Wed, 25 Jan 2012 11:03:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Numis maintains 37p price target ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</link>
<description><![CDATA[<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ]]></description>
<pubDate>Mon, 16 Jan 2012 10:32:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma profits forecast to meet expectations ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</link>
<description><![CDATA[<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>]]></description>
<pubDate>Mon, 16 Jan 2012 07:31:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Pre-Close Trading Update ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 16 Jan 2012 07:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".]]></description>
<pubDate>Mon, 16 Jan 2012 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</link>
<description><![CDATA[<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ]]></description>
<pubDate>Mon, 19 Dec 2011 08:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Acquisition of Brands ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 19 Dec 2011 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</link>
<description><![CDATA[<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>]]></description>
<pubDate>Thu, 08 Dec 2011 11:29:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma is “a stock for the times”, says Collins Stewart ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</link>
<description><![CDATA[<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>]]></description>
<pubDate>Thu, 17 Nov 2011 14:51:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.]]></description>
<pubDate>Thu, 17 Nov 2011 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[RNS press release - Exercise of Options ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</link>
<description><![CDATA[]]></description>
<pubDate>Fri, 21 Oct 2011 17:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</guid>
</item>
</channel>
",
"scripts_for_layout" => "",
"cakeDebug" => "",
"javascript" => JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL,
"html" => HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL,
"time" => TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL,
"form" => FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object,
"pai" => PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object,
"session" => SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337188087
SessionHelper::$sessionTime = 1337212087
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles",
"profile" => ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object,
"paginator" => PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object,
"ajax" => AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object
)
$loadHelpers = false
$cached = true
$loadedHelpers = array()
$facebookSession = 0
$searchHeader_limit = null
$company = array(
"Company" => array(
"id" => "8987",
"epic" => "APH",
"name" => "Alliance Pharma",
"is_sponsor" => "1",
"international_sponsorship" => "UK"
)
)
$brokerpresses = array(
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
)
)
$items = array(
array(
"id" => "120514aph2671d",
"title" => "RNS press release - Notification of Major Interest in Shares",
"pubdate" => "2012-05-14 11:09:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/"
),
array(
"id" => "120410aph0287b",
"title" => "RNS press release - Notice of AGM",
"pubdate" => "2012-04-10 12:02:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/"
),
array(
"id" => "1099",
"title" => "Media files - Alliance Pharma CEO looks forward to continued good growth prospects",
"pubdate" => "2012-03-30 13:56:00",
"seftitle" => "alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html",
"description" => "John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.",
"link" => "http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html"
),
array(
"id" => "120327aph1392a",
"title" => "RNS press release - Annual Report and Accounts",
"pubdate" => "2012-03-27 09:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/"
),
array(
"id" => "40601",
"title" => "News - Alliance Pharma: Underlying growth of business remains strong",
"pubdate" => "2012-03-22 08:24:00",
"seftitle" => "alliance-pharma-underlying-growth-of-business-remains-strong-40601.html",
"description" => "<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html"
),
array(
"id" => "120322aph8313z",
"title" => "RNS press release - Preliminary Results",
"pubdate" => "2012-03-22 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/"
),
array(
"id" => "120321aph7914z",
"title" => "RNS press release - CULS Conversion",
"pubdate" => "2012-03-21 13:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/"
),
array(
"id" => "120308aph9988y",
"title" => "RNS press release - CULS Conversion",
"pubdate" => "2012-03-08 16:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/"
),
array(
"id" => "120202aph6451w",
"title" => "RNS press release - Notification of Preliminary Results",
"pubdate" => "2012-02-02 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/"
),
array(
"id" => "38225",
"title" => "News - Alliance Pharma remains a ‘buy’ at Investec Securities",
"pubdate" => "2012-01-25 11:03:00",
"seftitle" => "alliance-pharma-remains-a-buy-at-investec-securities-38225.html",
"description" => "<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html"
),
array(
"id" => "37831",
"title" => "News - Alliance Pharma: Numis maintains 37p price target",
"pubdate" => "2012-01-16 10:32:00",
"seftitle" => "alliance-pharma-numis-maintains-37p-price-target-37831.html",
"description" => "<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html"
),
array(
"id" => "37808",
"title" => "News - Alliance Pharma profits forecast to meet expectations",
"pubdate" => "2012-01-16 07:31:00",
"seftitle" => "alliance-pharma-profits-forecast-to-meet-expectations-37808.html",
"description" => "<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html"
),
array(
"id" => "120116aph5822v",
"title" => "RNS press release - Pre-Close Trading Update",
"pubdate" => "2012-01-16 07:01:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/"
),
array(
"id" => "",
"title" => "Broker press",
"pubdate" => "2012-01-16 00:00:00",
"seftitle" => "",
"description" => "16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".",
"link" => ""
),
array(
"id" => "37101",
"title" => "News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln",
"pubdate" => "2011-12-19 08:01:00",
"seftitle" => "alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html",
"description" => "<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html"
),
array(
"id" => "111219aph2003u",
"title" => "RNS press release - Acquisition of Brands",
"pubdate" => "2011-12-19 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/"
),
array(
"id" => "36735",
"title" => "News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec",
"pubdate" => "2011-12-08 11:29:00",
"seftitle" => "alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html",
"description" => "<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html"
),
array(
"id" => "35766",
"title" => "News - Alliance Pharma is “a stock for the times”, says Collins Stewart",
"pubdate" => "2011-11-17 14:51:00",
"seftitle" => "alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html",
"description" => "<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html"
),
array(
"id" => "",
"title" => "Broker press",
"pubdate" => "2011-11-17 00:00:00",
"seftitle" => "",
"description" => "17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.",
"link" => ""
),
array(
"id" => "111021aph6645q",
"title" => "RNS press release - Exercise of Options",
"pubdate" => "2011-10-21 17:56:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/"
)
)
$title_for_layout = "Rss"
$content_for_layout = "<channel>
<title>Proactiveinvestors United Kingdom Alliance Pharma</title>
<link>http://www.proactiveinvestors.co.uk</link>
<description>Proactiveinvestors United Kingdom Alliance Pharma RSS feed
</description>
<language>en</language>
<pubDate>Wed, 16 May 2012 18:08:07 +0100</pubDate>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<generator>Genera CMS</generator>
<managingEditor>action@proactiveinvestors.com (Proactiveinvestors)</managingEditor>
<webMaster>action@proactiveinvestors.com (Proactiveinvestors)</webMaster>
<atom:link href="http://www.proactiveinvestors.co.uk/LON:APH/Alliance-Pharma/all_news" rel="self" type="application/rss+xml" />
<item>
<title><![CDATA[RNS press release - Notification of Major Interest in Shares ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 14 May 2012 11:09:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notice of AGM ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 10 Apr 2012 12:02:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</guid>
</item>
<item>
<title><![CDATA[Media files - Alliance Pharma CEO looks forward to continued good growth prospects ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</link>
<description><![CDATA[John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.]]></description>
<pubDate>Fri, 30 Mar 2012 13:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Annual Report and Accounts ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 27 Mar 2012 09:00:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Underlying growth of business remains strong ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</link>
<description><![CDATA[<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ]]></description>
<pubDate>Thu, 22 Mar 2012 08:24:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 22 Mar 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</link>
<description><![CDATA[]]></description>
<pubDate>Wed, 21 Mar 2012 13:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 08 Mar 2012 16:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notification of Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 02 Feb 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma remains a ‘buy’ at Investec Securities ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</link>
<description><![CDATA[<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ]]></description>
<pubDate>Wed, 25 Jan 2012 11:03:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Numis maintains 37p price target ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</link>
<description><![CDATA[<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ]]></description>
<pubDate>Mon, 16 Jan 2012 10:32:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma profits forecast to meet expectations ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</link>
<description><![CDATA[<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>]]></description>
<pubDate>Mon, 16 Jan 2012 07:31:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Pre-Close Trading Update ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 16 Jan 2012 07:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".]]></description>
<pubDate>Mon, 16 Jan 2012 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</link>
<description><![CDATA[<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ]]></description>
<pubDate>Mon, 19 Dec 2011 08:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Acquisition of Brands ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 19 Dec 2011 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</link>
<description><![CDATA[<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>]]></description>
<pubDate>Thu, 08 Dec 2011 11:29:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma is “a stock for the times”, says Collins Stewart ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</link>
<description><![CDATA[<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>]]></description>
<pubDate>Thu, 17 Nov 2011 14:51:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.]]></description>
<pubDate>Thu, 17 Nov 2011 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[RNS press release - Exercise of Options ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</link>
<description><![CDATA[]]></description>
<pubDate>Fri, 21 Oct 2011 17:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</guid>
</item>
</channel>
"
$scripts_for_layout = ""
$cakeDebug = ""
$javascript = JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL
$html = HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL
$time = TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL
$form = FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object
$pai = PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object
$session = SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337188087
SessionHelper::$sessionTime = 1337212087
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles"
$profile = ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object
$paginator = PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object
$ajax = AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper objectheader - [internal], line ?? include - APP/views/layouts/rss.ctp, line 2 View::_render() - CORE/cake/libs/view/view.php, line 667 View::renderLayout() - CORE/cake/libs/view/view.php, line 454 View::render() - CORE/cake/libs/view/view.php, line 388 Controller::render() - CORE/cake/libs/controller/controller.php, line 806 Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 230 Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194 [main] - APP/webroot/index.php, line 91
Warning (2): Cannot modify header information - headers already sent by (output started at /home/paiuk/public_html/cake/basics.php:111) [APP/views/layouts/rss.ctp, line 3]
$___viewFn = "/home/paiuk/public_html/app/views/layouts/rss.ctp"
$___dataForView = array(
"facebookSession" => 0,
"searchHeader_limit" => null,
"company" => array(
"Company" => array()
),
"brokerpresses" => array(
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array()
),
"items" => array(
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array()
),
"title_for_layout" => "Rss",
"content_for_layout" => "<channel>
<title>Proactiveinvestors United Kingdom Alliance Pharma</title>
<link>http://www.proactiveinvestors.co.uk</link>
<description>Proactiveinvestors United Kingdom Alliance Pharma RSS feed
</description>
<language>en</language>
<pubDate>Wed, 16 May 2012 18:08:07 +0100</pubDate>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<generator>Genera CMS</generator>
<managingEditor>action@proactiveinvestors.com (Proactiveinvestors)</managingEditor>
<webMaster>action@proactiveinvestors.com (Proactiveinvestors)</webMaster>
<atom:link href="http://www.proactiveinvestors.co.uk/LON:APH/Alliance-Pharma/all_news" rel="self" type="application/rss+xml" />
<item>
<title><![CDATA[RNS press release - Notification of Major Interest in Shares ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 14 May 2012 11:09:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notice of AGM ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 10 Apr 2012 12:02:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</guid>
</item>
<item>
<title><![CDATA[Media files - Alliance Pharma CEO looks forward to continued good growth prospects ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</link>
<description><![CDATA[John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.]]></description>
<pubDate>Fri, 30 Mar 2012 13:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Annual Report and Accounts ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 27 Mar 2012 09:00:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Underlying growth of business remains strong ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</link>
<description><![CDATA[<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ]]></description>
<pubDate>Thu, 22 Mar 2012 08:24:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 22 Mar 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</link>
<description><![CDATA[]]></description>
<pubDate>Wed, 21 Mar 2012 13:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 08 Mar 2012 16:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notification of Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 02 Feb 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma remains a ‘buy’ at Investec Securities ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</link>
<description><![CDATA[<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ]]></description>
<pubDate>Wed, 25 Jan 2012 11:03:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Numis maintains 37p price target ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</link>
<description><![CDATA[<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ]]></description>
<pubDate>Mon, 16 Jan 2012 10:32:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma profits forecast to meet expectations ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</link>
<description><![CDATA[<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>]]></description>
<pubDate>Mon, 16 Jan 2012 07:31:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Pre-Close Trading Update ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 16 Jan 2012 07:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".]]></description>
<pubDate>Mon, 16 Jan 2012 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</link>
<description><![CDATA[<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ]]></description>
<pubDate>Mon, 19 Dec 2011 08:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Acquisition of Brands ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 19 Dec 2011 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</link>
<description><![CDATA[<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>]]></description>
<pubDate>Thu, 08 Dec 2011 11:29:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma is “a stock for the times”, says Collins Stewart ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</link>
<description><![CDATA[<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>]]></description>
<pubDate>Thu, 17 Nov 2011 14:51:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.]]></description>
<pubDate>Thu, 17 Nov 2011 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[RNS press release - Exercise of Options ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</link>
<description><![CDATA[]]></description>
<pubDate>Fri, 21 Oct 2011 17:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</guid>
</item>
</channel>
",
"scripts_for_layout" => "",
"cakeDebug" => "",
"javascript" => JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL,
"html" => HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL,
"time" => TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL,
"form" => FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object,
"pai" => PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object,
"session" => SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337188087
SessionHelper::$sessionTime = 1337212087
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles",
"profile" => ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object,
"paginator" => PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object,
"ajax" => AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object
)
$loadHelpers = false
$cached = true
$loadedHelpers = array()
$facebookSession = 0
$searchHeader_limit = null
$company = array(
"Company" => array(
"id" => "8987",
"epic" => "APH",
"name" => "Alliance Pharma",
"is_sponsor" => "1",
"international_sponsorship" => "UK"
)
)
$brokerpresses = array(
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
)
)
$items = array(
array(
"id" => "120514aph2671d",
"title" => "RNS press release - Notification of Major Interest in Shares",
"pubdate" => "2012-05-14 11:09:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/"
),
array(
"id" => "120410aph0287b",
"title" => "RNS press release - Notice of AGM",
"pubdate" => "2012-04-10 12:02:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/"
),
array(
"id" => "1099",
"title" => "Media files - Alliance Pharma CEO looks forward to continued good growth prospects",
"pubdate" => "2012-03-30 13:56:00",
"seftitle" => "alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html",
"description" => "John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.",
"link" => "http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html"
),
array(
"id" => "120327aph1392a",
"title" => "RNS press release - Annual Report and Accounts",
"pubdate" => "2012-03-27 09:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/"
),
array(
"id" => "40601",
"title" => "News - Alliance Pharma: Underlying growth of business remains strong",
"pubdate" => "2012-03-22 08:24:00",
"seftitle" => "alliance-pharma-underlying-growth-of-business-remains-strong-40601.html",
"description" => "<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html"
),
array(
"id" => "120322aph8313z",
"title" => "RNS press release - Preliminary Results",
"pubdate" => "2012-03-22 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/"
),
array(
"id" => "120321aph7914z",
"title" => "RNS press release - CULS Conversion",
"pubdate" => "2012-03-21 13:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/"
),
array(
"id" => "120308aph9988y",
"title" => "RNS press release - CULS Conversion",
"pubdate" => "2012-03-08 16:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/"
),
array(
"id" => "120202aph6451w",
"title" => "RNS press release - Notification of Preliminary Results",
"pubdate" => "2012-02-02 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/"
),
array(
"id" => "38225",
"title" => "News - Alliance Pharma remains a ‘buy’ at Investec Securities",
"pubdate" => "2012-01-25 11:03:00",
"seftitle" => "alliance-pharma-remains-a-buy-at-investec-securities-38225.html",
"description" => "<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html"
),
array(
"id" => "37831",
"title" => "News - Alliance Pharma: Numis maintains 37p price target",
"pubdate" => "2012-01-16 10:32:00",
"seftitle" => "alliance-pharma-numis-maintains-37p-price-target-37831.html",
"description" => "<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html"
),
array(
"id" => "37808",
"title" => "News - Alliance Pharma profits forecast to meet expectations",
"pubdate" => "2012-01-16 07:31:00",
"seftitle" => "alliance-pharma-profits-forecast-to-meet-expectations-37808.html",
"description" => "<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html"
),
array(
"id" => "120116aph5822v",
"title" => "RNS press release - Pre-Close Trading Update",
"pubdate" => "2012-01-16 07:01:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/"
),
array(
"id" => "",
"title" => "Broker press",
"pubdate" => "2012-01-16 00:00:00",
"seftitle" => "",
"description" => "16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".",
"link" => ""
),
array(
"id" => "37101",
"title" => "News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln",
"pubdate" => "2011-12-19 08:01:00",
"seftitle" => "alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html",
"description" => "<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html"
),
array(
"id" => "111219aph2003u",
"title" => "RNS press release - Acquisition of Brands",
"pubdate" => "2011-12-19 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/"
),
array(
"id" => "36735",
"title" => "News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec",
"pubdate" => "2011-12-08 11:29:00",
"seftitle" => "alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html",
"description" => "<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html"
),
array(
"id" => "35766",
"title" => "News - Alliance Pharma is “a stock for the times”, says Collins Stewart",
"pubdate" => "2011-11-17 14:51:00",
"seftitle" => "alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html",
"description" => "<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html"
),
array(
"id" => "",
"title" => "Broker press",
"pubdate" => "2011-11-17 00:00:00",
"seftitle" => "",
"description" => "17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.",
"link" => ""
),
array(
"id" => "111021aph6645q",
"title" => "RNS press release - Exercise of Options",
"pubdate" => "2011-10-21 17:56:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/"
)
)
$title_for_layout = "Rss"
$content_for_layout = "<channel>
<title>Proactiveinvestors United Kingdom Alliance Pharma</title>
<link>http://www.proactiveinvestors.co.uk</link>
<description>Proactiveinvestors United Kingdom Alliance Pharma RSS feed
</description>
<language>en</language>
<pubDate>Wed, 16 May 2012 18:08:07 +0100</pubDate>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<generator>Genera CMS</generator>
<managingEditor>action@proactiveinvestors.com (Proactiveinvestors)</managingEditor>
<webMaster>action@proactiveinvestors.com (Proactiveinvestors)</webMaster>
<atom:link href="http://www.proactiveinvestors.co.uk/LON:APH/Alliance-Pharma/all_news" rel="self" type="application/rss+xml" />
<item>
<title><![CDATA[RNS press release - Notification of Major Interest in Shares ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 14 May 2012 11:09:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notice of AGM ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 10 Apr 2012 12:02:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</guid>
</item>
<item>
<title><![CDATA[Media files - Alliance Pharma CEO looks forward to continued good growth prospects ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</link>
<description><![CDATA[John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.]]></description>
<pubDate>Fri, 30 Mar 2012 13:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Annual Report and Accounts ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 27 Mar 2012 09:00:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Underlying growth of business remains strong ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</link>
<description><![CDATA[<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ]]></description>
<pubDate>Thu, 22 Mar 2012 08:24:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 22 Mar 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</link>
<description><![CDATA[]]></description>
<pubDate>Wed, 21 Mar 2012 13:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 08 Mar 2012 16:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notification of Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 02 Feb 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma remains a ‘buy’ at Investec Securities ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</link>
<description><![CDATA[<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ]]></description>
<pubDate>Wed, 25 Jan 2012 11:03:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Numis maintains 37p price target ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</link>
<description><![CDATA[<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ]]></description>
<pubDate>Mon, 16 Jan 2012 10:32:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma profits forecast to meet expectations ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</link>
<description><![CDATA[<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>]]></description>
<pubDate>Mon, 16 Jan 2012 07:31:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Pre-Close Trading Update ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 16 Jan 2012 07:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".]]></description>
<pubDate>Mon, 16 Jan 2012 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</link>
<description><![CDATA[<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ]]></description>
<pubDate>Mon, 19 Dec 2011 08:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Acquisition of Brands ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 19 Dec 2011 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</link>
<description><![CDATA[<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>]]></description>
<pubDate>Thu, 08 Dec 2011 11:29:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma is “a stock for the times”, says Collins Stewart ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</link>
<description><![CDATA[<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>]]></description>
<pubDate>Thu, 17 Nov 2011 14:51:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.]]></description>
<pubDate>Thu, 17 Nov 2011 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[RNS press release - Exercise of Options ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</link>
<description><![CDATA[]]></description>
<pubDate>Fri, 21 Oct 2011 17:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</guid>
</item>
</channel>
"
$scripts_for_layout = ""
$cakeDebug = ""
$javascript = JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL
$html = HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL
$time = TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL
$form = FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object
$pai = PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object
$session = SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337188087
SessionHelper::$sessionTime = 1337212087
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles"
$profile = ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object
$paginator = PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object
$ajax = AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper objectheader - [internal], line ?? include - APP/views/layouts/rss.ctp, line 3 View::_render() - CORE/cake/libs/view/view.php, line 667 View::renderLayout() - CORE/cake/libs/view/view.php, line 454 View::render() - CORE/cake/libs/view/view.php, line 388 Controller::render() - CORE/cake/libs/controller/controller.php, line 806 Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 230 Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194 [main] - APP/webroot/index.php, line 91
Warning (2): Cannot modify header information - headers already sent by (output started at /home/paiuk/public_html/cake/basics.php:111) [APP/views/layouts/rss.ctp, line 4]
$___viewFn = "/home/paiuk/public_html/app/views/layouts/rss.ctp"
$___dataForView = array(
"facebookSession" => 0,
"searchHeader_limit" => null,
"company" => array(
"Company" => array()
),
"brokerpresses" => array(
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array()
),
"items" => array(
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array(),
array()
),
"title_for_layout" => "Rss",
"content_for_layout" => "<channel>
<title>Proactiveinvestors United Kingdom Alliance Pharma</title>
<link>http://www.proactiveinvestors.co.uk</link>
<description>Proactiveinvestors United Kingdom Alliance Pharma RSS feed
</description>
<language>en</language>
<pubDate>Wed, 16 May 2012 18:08:07 +0100</pubDate>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<generator>Genera CMS</generator>
<managingEditor>action@proactiveinvestors.com (Proactiveinvestors)</managingEditor>
<webMaster>action@proactiveinvestors.com (Proactiveinvestors)</webMaster>
<atom:link href="http://www.proactiveinvestors.co.uk/LON:APH/Alliance-Pharma/all_news" rel="self" type="application/rss+xml" />
<item>
<title><![CDATA[RNS press release - Notification of Major Interest in Shares ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 14 May 2012 11:09:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notice of AGM ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 10 Apr 2012 12:02:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</guid>
</item>
<item>
<title><![CDATA[Media files - Alliance Pharma CEO looks forward to continued good growth prospects ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</link>
<description><![CDATA[John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.]]></description>
<pubDate>Fri, 30 Mar 2012 13:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Annual Report and Accounts ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 27 Mar 2012 09:00:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Underlying growth of business remains strong ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</link>
<description><![CDATA[<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ]]></description>
<pubDate>Thu, 22 Mar 2012 08:24:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 22 Mar 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</link>
<description><![CDATA[]]></description>
<pubDate>Wed, 21 Mar 2012 13:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 08 Mar 2012 16:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notification of Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 02 Feb 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma remains a ‘buy’ at Investec Securities ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</link>
<description><![CDATA[<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ]]></description>
<pubDate>Wed, 25 Jan 2012 11:03:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Numis maintains 37p price target ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</link>
<description><![CDATA[<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ]]></description>
<pubDate>Mon, 16 Jan 2012 10:32:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma profits forecast to meet expectations ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</link>
<description><![CDATA[<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>]]></description>
<pubDate>Mon, 16 Jan 2012 07:31:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Pre-Close Trading Update ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 16 Jan 2012 07:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".]]></description>
<pubDate>Mon, 16 Jan 2012 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</link>
<description><![CDATA[<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ]]></description>
<pubDate>Mon, 19 Dec 2011 08:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Acquisition of Brands ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 19 Dec 2011 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</link>
<description><![CDATA[<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>]]></description>
<pubDate>Thu, 08 Dec 2011 11:29:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma is “a stock for the times”, says Collins Stewart ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</link>
<description><![CDATA[<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>]]></description>
<pubDate>Thu, 17 Nov 2011 14:51:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.]]></description>
<pubDate>Thu, 17 Nov 2011 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[RNS press release - Exercise of Options ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</link>
<description><![CDATA[]]></description>
<pubDate>Fri, 21 Oct 2011 17:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</guid>
</item>
</channel>
",
"scripts_for_layout" => "",
"cakeDebug" => "",
"javascript" => JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL,
"html" => HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL,
"time" => TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL,
"form" => FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object,
"pai" => PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object,
"session" => SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337188087
SessionHelper::$sessionTime = 1337212087
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles",
"profile" => ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object,
"paginator" => PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object,
"ajax" => AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object
)
$loadHelpers = false
$cached = true
$loadedHelpers = array()
$facebookSession = 0
$searchHeader_limit = null
$company = array(
"Company" => array(
"id" => "8987",
"epic" => "APH",
"name" => "Alliance Pharma",
"is_sponsor" => "1",
"international_sponsorship" => "UK"
)
)
$brokerpresses = array(
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
),
array(
"Brokerpress" => array()
)
)
$items = array(
array(
"id" => "120514aph2671d",
"title" => "RNS press release - Notification of Major Interest in Shares",
"pubdate" => "2012-05-14 11:09:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/"
),
array(
"id" => "120410aph0287b",
"title" => "RNS press release - Notice of AGM",
"pubdate" => "2012-04-10 12:02:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/"
),
array(
"id" => "1099",
"title" => "Media files - Alliance Pharma CEO looks forward to continued good growth prospects",
"pubdate" => "2012-03-30 13:56:00",
"seftitle" => "alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html",
"description" => "John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.",
"link" => "http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html"
),
array(
"id" => "120327aph1392a",
"title" => "RNS press release - Annual Report and Accounts",
"pubdate" => "2012-03-27 09:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/"
),
array(
"id" => "40601",
"title" => "News - Alliance Pharma: Underlying growth of business remains strong",
"pubdate" => "2012-03-22 08:24:00",
"seftitle" => "alliance-pharma-underlying-growth-of-business-remains-strong-40601.html",
"description" => "<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html"
),
array(
"id" => "120322aph8313z",
"title" => "RNS press release - Preliminary Results",
"pubdate" => "2012-03-22 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/"
),
array(
"id" => "120321aph7914z",
"title" => "RNS press release - CULS Conversion",
"pubdate" => "2012-03-21 13:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/"
),
array(
"id" => "120308aph9988y",
"title" => "RNS press release - CULS Conversion",
"pubdate" => "2012-03-08 16:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/"
),
array(
"id" => "120202aph6451w",
"title" => "RNS press release - Notification of Preliminary Results",
"pubdate" => "2012-02-02 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/"
),
array(
"id" => "38225",
"title" => "News - Alliance Pharma remains a ‘buy’ at Investec Securities",
"pubdate" => "2012-01-25 11:03:00",
"seftitle" => "alliance-pharma-remains-a-buy-at-investec-securities-38225.html",
"description" => "<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html"
),
array(
"id" => "37831",
"title" => "News - Alliance Pharma: Numis maintains 37p price target",
"pubdate" => "2012-01-16 10:32:00",
"seftitle" => "alliance-pharma-numis-maintains-37p-price-target-37831.html",
"description" => "<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html"
),
array(
"id" => "37808",
"title" => "News - Alliance Pharma profits forecast to meet expectations",
"pubdate" => "2012-01-16 07:31:00",
"seftitle" => "alliance-pharma-profits-forecast-to-meet-expectations-37808.html",
"description" => "<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html"
),
array(
"id" => "120116aph5822v",
"title" => "RNS press release - Pre-Close Trading Update",
"pubdate" => "2012-01-16 07:01:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/"
),
array(
"id" => "",
"title" => "Broker press",
"pubdate" => "2012-01-16 00:00:00",
"seftitle" => "",
"description" => "16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".",
"link" => ""
),
array(
"id" => "37101",
"title" => "News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln",
"pubdate" => "2011-12-19 08:01:00",
"seftitle" => "alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html",
"description" => "<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html"
),
array(
"id" => "111219aph2003u",
"title" => "RNS press release - Acquisition of Brands",
"pubdate" => "2011-12-19 07:00:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/"
),
array(
"id" => "36735",
"title" => "News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec",
"pubdate" => "2011-12-08 11:29:00",
"seftitle" => "alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html",
"description" => "<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html"
),
array(
"id" => "35766",
"title" => "News - Alliance Pharma is “a stock for the times”, says Collins Stewart",
"pubdate" => "2011-11-17 14:51:00",
"seftitle" => "alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html",
"description" => "<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>",
"link" => "http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html"
),
array(
"id" => "",
"title" => "Broker press",
"pubdate" => "2011-11-17 00:00:00",
"seftitle" => "",
"description" => "17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.",
"link" => ""
),
array(
"id" => "111021aph6645q",
"title" => "RNS press release - Exercise of Options",
"pubdate" => "2011-10-21 17:56:00",
"seftitle" => "",
"description" => "",
"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/"
)
)
$title_for_layout = "Rss"
$content_for_layout = "<channel>
<title>Proactiveinvestors United Kingdom Alliance Pharma</title>
<link>http://www.proactiveinvestors.co.uk</link>
<description>Proactiveinvestors United Kingdom Alliance Pharma RSS feed
</description>
<language>en</language>
<pubDate>Wed, 16 May 2012 18:08:07 +0100</pubDate>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<generator>Genera CMS</generator>
<managingEditor>action@proactiveinvestors.com (Proactiveinvestors)</managingEditor>
<webMaster>action@proactiveinvestors.com (Proactiveinvestors)</webMaster>
<atom:link href="http://www.proactiveinvestors.co.uk/LON:APH/Alliance-Pharma/all_news" rel="self" type="application/rss+xml" />
<item>
<title><![CDATA[RNS press release - Notification of Major Interest in Shares ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 14 May 2012 11:09:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120514aph2671d/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notice of AGM ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 10 Apr 2012 12:02:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120410aph0287b/</guid>
</item>
<item>
<title><![CDATA[Media files - Alliance Pharma CEO looks forward to continued good growth prospects ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</link>
<description><![CDATA[John Dawson, CEO of Alliance Pharma (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) tells Proactiveinvestors that the future is looking good. With sales rising at 19% compound pa over the last five years, rising profitability, falling debt and a "progressive dividend strategy", everything is there. John says that he and his team will just continue proving the business model, making more acquisitions and then let the market catch up.]]></description>
<pubDate>Fri, 30 Mar 2012 13:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/stocktube/1099/alliance-pharma-ceo-looks-forward-to-continued-good-growth-prospects-1099.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Annual Report and Accounts ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</link>
<description><![CDATA[]]></description>
<pubDate>Tue, 27 Mar 2012 09:00:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120327aph1392a/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Underlying growth of business remains strong ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</link>
<description><![CDATA[<p>Branded medicines seller <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) is actively seeking further acquisitions to support growth in 2012, as it revealed solid figures for the past year.<br /><br />The company reported strong underlying growth and as a nod to future confidence increased its proposed final dividend 25 per cent to 0.50 pence per share.<br /><br />It comes after the company made three acquisitions last year with combined sales of £4.7 million. Promoted products Hydromol and ImmuCyst achieved like-for-like sales growth of 25 per cent and 12 per cent respectively<br /><br />Chairman Michael Gatenby told investors today: "The underlying growth of our business remains strong and cash generation remains healthy. <br /><br />"We were particularly pleased with the sales growth of our promoted products coupled with the dependable sales of our core products. <br /><br />"We successfully completed three acquisitions during the year and continue to seek and evaluate further acquisition opportunities."<br /><br />As anticipated, sales for the year to December 31 were down 8 per cent at £46.0 million, while underlying sales, excluding Deltacortril, were up 13 per cent. The reduction in Deltacortril was partially offset by good organic growth in other products, the firm said.<br /><br />Pre-tax profit stood at £10.7 million (2010: £12.9mln).<br /><br />Last year saw the firm continue its strategy with three completed acquisitions, which added ten products. <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> pointed out that it had successfully completed acquisitions each year for the past six years.<br /><br />Over those six years, its sales have grown at an average compound rate of 21 per cent per year, of which 14 per cent has come from acquisitions.<br /><br />Gatenby said he regarded acquisitions as an integral part of the business model. <br /><br />"With a strong financing position, including £13m of headroom in our revolving credit facility, we are now able to contemplate targets larger than any of those we have acquired so far. Market conditions remain favourable, and we are optimistic about the prospects for further attractive acquisitions in 2012."<br /><br />In a note, broker finnCap, which rates the stock a 'buy' said the results were "broadly in line" with its estimates, adding it expected the firm to perform slightly ahead of 2011 in the current year, then to return to stronger growth in the subsequent year.<br /><br />The broker targets a price of 36 pence for the stock.</p> ]]></description>
<pubDate>Thu, 22 Mar 2012 08:24:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/40601/alliance-pharma-underlying-growth-of-business-remains-strong-40601.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 22 Mar 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120322aph8313z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</link>
<description><![CDATA[]]></description>
<pubDate>Wed, 21 Mar 2012 13:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120321aph7914z/</guid>
</item>
<item>
<title><![CDATA[RNS press release - CULS Conversion ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 08 Mar 2012 16:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120308aph9988y/</guid>
</item>
<item>
<title><![CDATA[RNS press release - Notification of Preliminary Results ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</link>
<description><![CDATA[]]></description>
<pubDate>Thu, 02 Feb 2012 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120202aph6451w/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma remains a ‘buy’ at Investec Securities ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</link>
<description><![CDATA[<p>Broker <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> Securities has reiterated its ‘buy’ stance on branded medicines seller <a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) after last week’s pre-close trading statement, and said the recent sell-off has created a more attractive buying opportunity.<br /><br />Alliance announced last week that pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended. <br /><br />The speciality pharmaceutical group said its Deltacortril steroid pill continued to be affected by increased competition. Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of (steroid pill) Deltacortril and the risk to (coted aspirin tablet) Nu-Seals,” the company had said.<br /><br />In a note, <a href="http://www.proactiveinvestors.co.uk/companies/overview/4268/Investec" class="companyPopupTrigger" rel="4268">Investec</a> said the update saw its revenue forecasts marginally exceeded, but the net effect of minor operational issues, a slightly unfavourable outlook for Nu-Seals and recent acquisitions drive minor downgrades to its forecasts, which were at the higher end of consensus. <br /><br />While the new forecasts lead the broker to reduce its price target to 34 pence from 37 pence, the target still supports a ‘buy’ recommendation. Alliance was last trading at 28.7 pence.<br /><br />Analyst Nicholas Keher believes there is potential for further share price rises from acquisitions, given Alliance’s fire-power with £13.5 million of its revolving credit facility still untapped and the active search under way.<br /><br />“Liquidity remains an issue, but has exaggerated the (recent) sell-off and created a more attractive buying opportunity in our view,” he added.</p> ]]></description>
<pubDate>Wed, 25 Jan 2012 11:03:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/38225/alliance-pharma-remains-a-buy-at-investec-securities-38225.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma: Numis maintains 37p price target ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</link>
<description><![CDATA[<p>Broker Numis maintains its price target of 37 pence a share on <a href="http://proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>), adding it saw potential for further 'earnings accretive' product acquisitions from the firm.<br /><br />The firm, which sells branded medicines, said pre-tax profits would be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.<br /><br />In a pre-close trading update the speciality pharma group said its Deltacortril steroid pill continued to be affected by increased competition. <br /><br />Total sales for the 12 months to December 31 were £4.7 million, with £1.1 million coming in the second half.<br /><br />However it added that sales of its Hydromol cream and ImmuCyst for bladder cancer “continued to grow well”.<br /><br />Revenues from Nu-Seals, a coated aspirin tablet used as an anti-clotting agent sold mainly in the Republic of Ireland, were up 14 per cent to £5.4 million. <br /><br />“We are implementing a number of efficiency measures and other cost savings and believe that these steps, together with the impact of the three acquisitions completed in 2011, should largely compensate for the impact of the further reduction in sales of Deltacortril and the risk to Nu-Seals,” the company said.<br /><br />Analyst Charles Weston, of Numis, said that the broker was keeping its pre-tax profit estimate of £10.7 million for the year just gone. And for 2012, he said he was lifting its sales forecast from £45.9 million to £47.1million.<br /><br />But, he added, that given the potentially lower mix of high margin Deltacortril and Nu-Seals, its PBT (profit before tax) forecast fell from £11.1 million to £10.9 million.<br /><br />"This includes the effect of further efficiency measures that management is implementing to face these head-winds. Our 2013 profit forecasts remain largely unchanged," said the analyst.</p> ]]></description>
<pubDate>Mon, 16 Jan 2012 10:32:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37831/alliance-pharma-numis-maintains-37p-price-target-37831.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma profits forecast to meet expectations ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</link>
<description><![CDATA[<p>Alliance Pharma said pre-tax profits will be in line with market expectations with annual revenues predicted to be around £46 million for the year just ended.</p>]]></description>
<pubDate>Mon, 16 Jan 2012 07:31:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37808/alliance-pharma-profits-forecast-to-meet-expectations-37808.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Pre-Close Trading Update ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 16 Jan 2012 07:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/120116aph5822v/</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[16.01.12 :-1.75, (28.75) Brewin Dolphin downgrades its rating to "hold" from "add".]]></description>
<pubDate>Mon, 16 Jan 2012 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma acquires Quinoderm and Ceanel brands for £1.5 mln ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</link>
<description><![CDATA[<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/8987/Alliance+Pharma" class="companyPopupTrigger" rel="8987">Alliance Pharma</a> (<a href="/companies/overview/8987/alliance-pharma-8987.html" class="companyPopupTrigger" rel="8987">LON:APH</a>) has expanded its product portfolio with the acquisition of two skin care brands.</p>
<p>This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis. </p>
<p>The two brands contributed sales of £600,000 in the twelve months to September 30 2011.</p>
<p>"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.</p>
<p>"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."</p>
<p>The deal is being funded via a £20 million revolving credit facility which was set up last November. </p>
<p>The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.</p>
</p> ]]></description>
<pubDate>Mon, 19 Dec 2011 08:01:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/37101/alliance-pharma-acquires-quinoderm-and-ceanel-brands-for-15-mln-37101.html</guid>
</item>
<item>
<title><![CDATA[RNS press release - Acquisition of Brands ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</link>
<description><![CDATA[]]></description>
<pubDate>Mon, 19 Dec 2011 07:00:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111219aph2003u/</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma’s business model “misunderstood” by stock market, says Investec ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</link>
<description><![CDATA[<p>The pharmaceutical firm is defensive and cash generative, says the broker, while the implications of lost sales from its Deltacortril product are not understood by investors</p>]]></description>
<pubDate>Thu, 08 Dec 2011 11:29:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/36735/alliance-pharmas-business-model-misunderstood-by-stock-market-says-investec-36735.html</guid>
</item>
<item>
<title><![CDATA[News - Alliance Pharma is “a stock for the times”, says Collins Stewart ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</link>
<description><![CDATA[<p>The broker says that the life sciences firm demonstrates solid underlying revenue growth with strong cash generation and a progressive dividend policy</p>]]></description>
<pubDate>Thu, 17 Nov 2011 14:51:00 +0000</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/news/35766/alliance-pharma-is-a-stock-for-the-times-says-collins-stewart-35766.html</guid>
</item>
<item>
<title><![CDATA[Broker press ]]></title>
<link></link>
<description><![CDATA[17.11.11 :+0, (29.5) Collins Stewart initiates buy on Alliance Pharma, target price 36p.]]></description>
<pubDate>Thu, 17 Nov 2011 00:00:00 +0000</pubDate>
<guid></guid>
</item>
<item>
<title><![CDATA[RNS press release - Exercise of Options ]]></title>
<link>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</link>
<description><![CDATA[]]></description>
<pubDate>Fri, 21 Oct 2011 17:56:00 +0100</pubDate>
<guid>http://www.proactiveinvestors.co.uk/companies/rns/111021aph6645q/</guid>
</item>
</channel>
"
$scripts_for_layout = ""
$cakeDebug = ""
$javascript = JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL
$html = HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL
$time = TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL
$form = FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object
$pai = PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object
$session = SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337188087
SessionHelper::$sessionTime = 1337212087
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles"
$profile = ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object
$paginator = PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object
$ajax = AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:APH/Alliance-Pharma/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper objectheader - [internal], line ?? include - APP/views/layouts/rss.ctp, line 4 View::_render() - CORE/cake/libs/view/view.php, line 667 View::renderLayout() - CORE/cake/libs/view/view.php, line 454 View::render() - CORE/cake/libs/view/view.php, line 388 Controller::render() - CORE/cake/libs/controller/controller.php, line 806 Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 230 Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194 [main] - APP/webroot/index.php, line 91
Alliance Pharma (LON:APH) has expanded its product portfolio with the acquisition of two skin care brands.
This morning it revealed the deal to acquire the Quinoderm and Ceanel brands from Ferndale Pharmaceuticals Ltd for £1.5m in cash. Quinoderm is a treatment for acne and Ceanel is a shampoo treatment for scalp psoriasis.
The two brands contributed sales of £600,000 in the twelve months to September 30 2011.
"We are delighted to announce this acquisition, which extends our Dermatology portfolio. Quinoderm complements our existing product Rizuderm (isotretinoin), a treatment for severe acne acquired in September this year,” said chief executive John Dawson.
"Today's acquisition, which represents our third transaction this year, is expected to be earnings enhancing in 2012. We continue to evaluate further opportunities to broaden our product portfolio."
The deal is being funded via a £20 million revolving credit facility which was set up last November.
The facility was established to support the group’s acquisition strategy. Today it said that £6.5 million of the facility has now been used.
]]>